CCTA

ARTRYA SIGNS FIRST U.S. HOSPITAL CLINICAL PARTNERSHIP WITH HUNTSVILLE HEART CENTER

Retrieved on: 
Tuesday, May 10, 2022
Australian Securities Exchange, Nasiriyah Heart Center, Deep learning, LLC, Algorithm, Coronary artery disease, AYA, Company, Degenerative disease, Biomarker, Physician, Moyamoya disease, CCTA, Patient, Partnership, CT, Diagnosis, MD, Technology, AI, ASX, Risk, Intelligence, Willow, Medical device, Medical imaging, Pharmaceutical industry

HUNTSVILLE, Ala., May 10, 2022 /PRNewswire/ -- Artrya Ltd, creator of the AI-based cardiac software solution Artrya Salix, today announced its first U.S. clinical partnership with Alabama-based Huntsville Heart Center, Inc, a national leader in coronary computed tomography angiography (CCTA) that treats more than 80,000 cardiac patients per year.

Key Points: 
  • HUNTSVILLE, Ala., May 10, 2022 /PRNewswire/ -- Artrya Ltd, creator of the AI-based cardiac software solution Artrya Salix, today announced its first U.S. clinical partnership with Alabama-based Huntsville Heart Center, Inc, a national leader in coronary computed tomography angiography (CCTA) that treats more than 80,000 cardiac patients per year.
  • As part of the initial agreement, Heart Center Research, LLC, a division of Huntsville Heart Center, will conduct a study to determine the efficacy of Artrya' s technology.
  • In the study, Heart Center researchers will utilize CT scans that were previously obtained for indicated clinical purposes.
  • Artrya USA Co-CEO's, Jory Tremblay and Ted Schwab, said: "This is the Company's first clinical partnership in the U.S., and we are pleased that such a well-regarded heart center has joined in our mission to create better detection of the world's leading killer -- heart disease."

DGAP-News: California Cable & Telecommunications Association Announces New President

Retrieved on: 
Tuesday, April 12, 2022
Janus, People, Judicial Council of California, CMA, LinkedIn, Jesse, American Federation of State, County and Municipal Employees, Board, Association, Environment, California State University, Judicial Council, Board of directors, Senior, Communication studies, Employment, Government, California Medical Association, Industry, MBA, Telecommunication, Policy, Bachelor of Arts, University, AFSCME, Politics, California State Legislature, CCTA, European Competitive Telecommunications Association, Internet service provider, Management

After an extensive nationwide search, the California Cable & Telecommunications Association ('CCTA') , a leader in the development of video, broadband and communications policy in California, announced today that Janus Norman has been selected as President of the Association.

Key Points: 
  • After an extensive nationwide search, the California Cable & Telecommunications Association ('CCTA') , a leader in the development of video, broadband and communications policy in California, announced today that Janus Norman has been selected as President of the Association.
  • Norman has over a decade of legislative and government experience in California, most recently serving as the Senior Vice President of the California Medical Association (CMA) where he oversaw all legislative and political activities for the organization.
  • 'CCTA is uniquely positioned to capitalize on the ever-changing broadband and telecommunications environment here in California.
  • For more on his background, please visit his LinkedIn profile: Janus Norman on LinkedIn
    About the California Cable & Telecommunications Association:
    The California Cable & Telecommunications Association (CCTA) is the industry's largest state cable and telecommunications association.

Ziosoft to Feature ECVct and LAAO Advanced Visualization at American College of Cardiology Annual Convention

Retrieved on: 
Friday, April 1, 2022
Disease, ACC, Heart, Marketing, The San Diego Union-Tribune, TAVR, AV, Coronary CT angiography, Ownership, Left atrial appendage occlusion, Abraxis BioScience, Amyloid, Program, Pathology, Percutaneous aortic valve replacement, Atrial appendage, Man, MD, Woman, ECV, Stroke, American College, ImmunityBio, Coronary, Weeping Angel, Solution, Atrial fibrillation, Amyloidosis, Efficiency, Protein, Patient, CCTA, Decision-making, Medical imaging, NantWorks

NEWARK, Calif., April 1, 2022 /PRNewswire-PRWeb/ -- Ziosoft, a pioneer and leader in 3D/4D advanced visualization, will feature its ECVct (Extracellular Volume Fraction with computed tomography) and LAAO (Left Atrial Appendage Occlusion) advanced visualization (AV) software at the annual American College of Cardiology (ACC) conference being held in Washington DC, April 2-4, 2022. Both capabilities are part of Ziosoft's extensive array of AV solutions for multiple applications and modalities on its flagship Ziostation2 platform.

Key Points: 
  • NEWARK, Calif., April 1, 2022 /PRNewswire-PRWeb/ -- Ziosoft, a pioneer and leader in 3D/4D advanced visualization, will feature its ECVct (Extracellular Volume Fraction with computed tomography) and LAAO (Left Atrial Appendage Occlusion) advanced visualization (AV) software at the annual American College of Cardiology (ACC) conference being held in Washington DC, April 2-4, 2022.
  • In addition to ECVct and LAAO, Ziosoft will be demonstrating its unique PhyZiodynamics 3D/4D solution as well as CT lung resection software.
  • "Zioflex enables a risk free entry into the utilization of highly advanced visualization and analytics contained within the Ziosoft platform," said Taitriya.
  • Ziosoft provides a comprehensive multi-modality, 3D/4D advanced processing and viewing solution for a wide variety of specialties.

Private Club Partners With Fountain Life to Create One of the World's First 'Biotech Bars'

Retrieved on: 
Tuesday, November 30, 2021
Patient, Gulf of Mexico, Heart, Insurance, CEO, Technology, Data collection, Death, Aneurysm, Exercise, Partnership, Oh Pray My Wings Are Gonna Fit Me Well, Health, Cancer, Â, Longevity, Therapy, Program, Neurodegeneration, Wellness, Artificial intelligence, GLOBE, Artery, Degenerative disease, CCTA, FDA, OS, Catalog, Walking, Fountain, Disease, Life, Quality of life, Medical device, Nightclub

Fountain OS empowers any business, from medical practices to country clubs, to create their own, white-labeled "Biotech Bar" and offer breakthrough live-saving diagnostics to their customers and community.

Key Points: 
  • Fountain OS empowers any business, from medical practices to country clubs, to create their own, white-labeled "Biotech Bar" and offer breakthrough live-saving diagnostics to their customers and community.
  • The program is now available on all smartphone platforms, offering club members a valuable extension to their existing club membership.
  • Fountain Life brings together the world's most renowned medical and health experts to boost longevity and performance - putting health back in healthcare.
  • Fountain Life's data-driven approach enables them to find illnesses including cancer, cardiac, metabolic, neurodegenerative disease early before they can cause harm.

Elucid Eyes Big Opportunity to Save Lives with Software Amidst Major Guideline Changes

Retrieved on: 
Friday, October 29, 2021
Nursing, Cardiology, Biotechnology, Technology, Health, General Health, Radiology, Medical Devices, Software, Hospitals, Hardware, MD, Biology, CCTA, LinkedIn, Ischemia, Guideline, Myocardial infarction, CAD, Patient, Journal of the American College of Cardiology, Cardiovascular disease, American Heart Association, RNA, Stenosis, Risk, Intelligence, Atherosclerosis, Plaque, Precision medicine, Atheroma, Joint committee, AI, Roemheld syndrome, Registry, Coronary artery disease, American College, Journal, Physician, Medical imaging, Medical device

For intermediate-risk patients with no known CAD, CCTA is now a class I recommendation for excluding atherosclerotic plaque and obstructive CAD (level of evidence A).

Key Points: 
  • For intermediate-risk patients with no known CAD, CCTA is now a class I recommendation for excluding atherosclerotic plaque and obstructive CAD (level of evidence A).
  • The evidence for CCTA is overwhelmingly positive and we are excited to see the guideline changes enacted with this document said Blake Richards, Elucid CEO, Congratulations to the committee for an exhaustive evaluation and excellent publication.
  • The use of scientific imaging supported by artificial intelligence to quantitate vessel wall biology will help the field move forward and save millions of lives each year.
  • ElucidVivo is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core.

Verizon, Nissan, CCTA collaborate on connected-vehicle technology for roadway safety

Retrieved on: 
Thursday, October 21, 2021
Safety, Research, Technology, Housing, CCTA, VZ, CA, RSS, Homeland Security Grant Program, Transport, Verizon Communications, AF Corse, Pedestrian, NYSE, Senior, ADS, Verizon Business, Environment, Solution, Nasdaq, GLOBE, Industrial, Mobile phone, Road, Renewable energy

BASKING RIDGE, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Verizon and Nissan North America’s Research and Advanced Engineering team have completed a research proof-of-concept demonstrating how sensor data from vehicles and surrounding infrastructure can be processed at the edge of Verizon’s wireless network and communicated back to vehicles for urgent driver notifications in near real time. The test successfully applied that process -- an example of cellular vehicle-to-everything communication (C-V2X) -- to scenarios in which drivers may find it difficult to see vulnerable pedestrians or oncoming traffic emerging from behind visual obstructions. The Contra Costa Transportation Authority (CCTA) will initiate validation of the technology for its Automated Driving Systems Grant Program, which would see the use case tested in controlled public environments in Contra Costa County toward potential live deployment upon validation.“Communication between vehicles and the environment around them, or C-V2X, will be one of the most important transportation innovations of the connected and autonomous future of driving,” said TJ Fox, Senior Vice President of Industrial IoT and Automotive, Verizon Business. “This proof of concept shows that edge computing with Verizon’s cellular network can help take the resource-intensive compute burden off vehicles and public infrastructure -- housing their software platforms and crunching their sensor data for them -- and can communicate data outward to prompt potentially lifesaving safety alerts or autonomous driving features in the car, all essentially in real time.”

Key Points: 
  • Making breakthroughs in products and technologies is a core piece of Nissans business, said Maarten Sierhuis, Ph.D., vice president, Nissan Technical Center North America.
  • The successful development and pilot of this research technology reinforces our commitment to helping keep drivers and passengers safe and the future of mobility.
  • Taking a proactive approach to safety is a priority for CCTA, and the technology were testing together will contribute toward making connected and automated vehicles a safe option for future travel.
  • Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is one of the worlds leading providers of technology and communications services.

HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE Trial

Retrieved on: 
Thursday, October 14, 2021
Death, CT, Technology, Degenerative disease, Diagnosis, Plaque, Silicon, Acute coronary syndrome, Heart, CCTA, 3D, Mount Sinai Hospital, Man, Rupture, Computational fluid dynamics, Multicenter Automatic Defibrillator Implantation Trial, MSA, Physician, IVUS, FACC, Algorithm, Woman, Interventional cardiology, Coronary artery disease, Intelligence, Trial of the century, Physiology, Patient, CAD, GLOBE, Muscle tissue, Anatomy, Kindai University, Moyamoya disease, Safety, CTA, DO, Principal, Deep learning, Cone Health, Mechanism, Analyse, Medical imaging

It is clear, however, that coronary plaque is the driving force behind understanding a patients risk of having a heart attack, said Dr. Meckel, lead Principal Investigator for REVEALPLAQUE at Bryan Heart.

Key Points: 
  • It is clear, however, that coronary plaque is the driving force behind understanding a patients risk of having a heart attack, said Dr. Meckel, lead Principal Investigator for REVEALPLAQUE at Bryan Heart.
  • To be able to accurately and non-invasively understand a patients plaque burden would be game changing in physicians abilities to save a patients life from a heart attack.
  • The REVEALPLAQUE trial is planned to enroll 250 patients with stable coronary artery disease from approximately 15 sites across the U.S. and Japan.
  • The HeartFlow FFRct Analysis is commercially available in the United States, UK, Canada, Europe and Japan.

Leading the Way in Smart Decisioning Solutions for Motor Finance

Retrieved on: 
Tuesday, January 22, 2019
Information technology management, Central Computer and Telecommunications Agency, HM Treasury, PRINCE2, CCTA, Computing, Information technology, Digital technology

Zoot's award-winning solution is a cutting-edge cloud-based decisioning platform with case management capabilities that address the client's changing needs and ensure an extraordinary end-customer experience.

Key Points: 
  • Zoot's award-winning solution is a cutting-edge cloud-based decisioning platform with case management capabilities that address the client's changing needs and ensure an extraordinary end-customer experience.
  • In addition, the platform automates complex decisioning strategies to achieve accurate real-time risk assessment, while incorporating credit management, affordability checks, anti-fraud measures and AML verification.
  • A CCTA judge highlighted this strength by commenting: "Instant decisioning tool that helps to automate lengthy, manual application assessment process.
  • The CCTA judges' commented about Zoot: "Leading the way in smart decisioning solutions for motor finance" and "Impressive analytics platform/solution with excellent results.